Scarica l'app Stockscreener
2.04
0.49%
0.01
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché SLS Giù?
Forum
Previsione
Frazionamento azionario
Precedente Chiudi:
$2.03
Aprire:
$2.06
Volume 24 ore:
4.92M
Relative Volume:
1.23
Capitalizzazione di mercato:
$290.58M
Reddito:
-
Utile/perdita netta:
$-37.34M
Rapporto P/E:
-1.50
EPS:
-1.36
Flusso di cassa netto:
$-36.91M
1 W Prestazione:
+12.09%
1M Prestazione:
+42.66%
6M Prestazione:
+22.89%
1 anno Prestazione:
+133.92%
Intervallo 1D:
$1.915
$2.08
Intervallo di 1 settimana:
$1.825
$2.12
Portata 52W:
$0.8335
$2.48
Sellas Life Sciences Group Inc Stock (SLS) Company Profile
Nome
Sellas Life Sciences Group Inc
Settore
Industria
Telefono
(646) 200-5278
Indirizzo
7 TIMES SQUARE, NEW YORK, NY
Confronta SLS con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
SLS
Sellas Life Sciences Group Inc
|
2.04 | 289.16M | 0 | -37.34M | -36.91M | -1.36 |
|
VRTX
Vertex Pharmaceuticals Inc
|
455.71 | 114.69B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
752.62 | 77.91B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ARGX
Argen X Se Adr
|
850.95 | 54.05B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
391.50 | 52.52B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
INSM
Insmed Inc
|
196.92 | 42.02B | 447.02M | -1.18B | -906.14M | -6.1812 |
Sellas Life Sciences Group Inc Stock (SLS) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2021-07-21 | Iniziato | Cantor Fitzgerald | Overweight |
| 2018-11-01 | Iniziato | Oppenheimer | Outperform |
| 2018-04-02 | Iniziato | H.C. Wainwright | Buy |
| 2018-03-19 | Aggiornamento | Maxim Group | Hold → Buy |
Sellas Life Sciences Group Inc Borsa (SLS) Ultime notizie
Why SELLAS Life Sciences Group (SLS) Is Up 12.6% After Encouraging SLS009 Phase 2 AML Data And What's Next - Yahoo Finance
Sellas Life Sciences draws retail buzz on SLS009 trial momentum – stock soars in pre-market - MSN
SELLAS Life Sciences Draws Retail Buzz On SLS009 Trial Momentum – Stock Soars In Pre-Market - Stocktwits
SELLAS Life Sciences: Clinical Trials Ignite Stock Interest - timothysykes.com
Sellas Life Sciences rises after reporting encouraging AML clinical results - MSN
Sellas Life Sciences stock jumps after promising AML treatment data By Investing.com - Investing.com Nigeria
Sellas Life Sciences stock jumps after promising AML treatment data - Investing.com
SELLAS Rises On Positive Phase 2 Data Of SLS009 In Relapsed/Refractory AML-MR - Nasdaq
Sellas Life Says Phase 2 Study of Cancer Combination Treatment Shows 'Clinically Meaningful' Activity; Shares Up Pre-Bell - marketscreener.com
SELLAS Life Sciences Presents Positive Phase 2 Data of SLS009 in Combination with AZA/VEN in Relapsed/Refractory AML-MR at ASH 2025 - The Manila Times
SELLAS Life Sciences Presents Positive Phase 2 Data of - GlobeNewswire
Trend Recap: Is SELLAS Life Sciences Group Inc RXK3 stock cheap by valuation metricsJuly 2025 Snapshot & Capital Efficiency Focused Ideas - moha.gov.vn
Should You Track Refex Industries Limited as a LongTerm Growth Play - earlytimes.in
Sellas Life Sciences Progress Sparks Optimism in Market - StocksToTrade
Blood Cancer Therapeutics Reach Critical Commercial and Clinical Inflection Points - KamloopsBCNow
Blood Cancer Therapeutics Reach Critical Commercial and Clinical Inflection Points - Benzinga
SELLAS Life Sciences Gains Momentum with Impressive Phase 2 Data and Financial Strength - timothysykes.com
How institutional buying supports SELLAS Life Sciences Group Inc. stockShare Buyback & High Accuracy Trade Alerts - Newser
How SELLAS Life Sciences Group Inc. (RXK3) stock compares with top peersQuarterly Profit Review & Stock Portfolio Risk Control - Newser
Is SELLAS Life Sciences Group Inc. (RXK3) stock cheap by valuation metrics2025 Investor Takeaways & Long-Term Safe Investment Plans - Newser
Is SELLAS Life Sciences Group Inc. (RXK3) stock a contrarian opportunityBreakout Watch & Weekly Chart Analysis and Guides - Newser
SELLAS Life Sciences Group Inc RXK3 Stock Analysis and ForecastStock Split Announcements & Technical + Fundamental = Smarter Investing - earlytimes.in
[EFFECT] SELLAS Life Sciences Group, Inc. SEC Filing - Stock Titan
SELLAS Advances AML Pipeline With GPS And SLS009 - RTTNews
Katherine Bach Kalin Acquires 63,400 Shares of SELLAS Life Sciences Group (NASDAQ:SLS) Stock - MarketBeat
Katherine Kalin Increases Stake in SELLAS Life Sciences Group Inc - GuruFocus
Kalin Katherine Bach buys SELLAS Life Sciences (SLS) shares By Investing.com - Investing.com Nigeria
Kalin Katherine Bach buys SELLAS Life Sciences (SLS) shares - Investing.com
[Form 4] SELLAS Life Sciences Group, Inc. Insider Trading Activity - Stock Titan
Analyzing SELLAS Life Sciences Group Inc. with risk reward ratio chartsWeekly Gains Report & Precise Swing Trade Alerts - newser.com
How SELLAS Life Sciences Group Inc. stock valuations compare to rivals2025 Macro Impact & Free Safe Capital Growth Stock Tips - newser.com
Does SELLAS Life Sciences Group Inc. show high probability of rebound - newser.com
SELLAS Life Sciences Group Sees Unusually Large Options Volume (NASDAQ:SLS) - MarketBeat
How risky is SELLAS Life Sciences Group Inc. stock nowPortfolio Performance Report & AI Forecast Swing Trade Picks - newser.com
Can SELLAS Life Sciences Group Inc. (RXK3) stock hold up in economic slowdown2025 Earnings Impact & Short-Term Trading Opportunity Alerts - newser.com
SELLAS Life Sciences Group Inc. stock prediction for this weekWeekly Investment Recap & Weekly Breakout Stock Alerts - newser.com
Why millennials buy SELLAS Life Sciences Group Inc. (RXK3) stock2025 Growth vs Value & Daily Momentum Trading Reports - newser.com
SELLAS Life Sciences Group Inc. stock trend forecastWeekly Trade Analysis & Verified Trade Idea Suggestions - newser.com
Is SELLAS Life Sciences Group Inc. showing signs of accumulationWeekly Trend Report & Entry and Exit Point Strategies - newser.com
Sellas Life Sciences Group Inc Azioni (SLS) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
0.36%
1.05%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):